Kieckhefer Group LLC Takes Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Kieckhefer Group LLC acquired a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,790 shares of the medical equipment provider’s stock, valued at approximately $5,632,000. Intuitive Surgical comprises about 3.4% of Kieckhefer Group LLC’s portfolio, making the stock its 7th largest holding.

Other hedge funds have also recently made changes to their positions in the company. Mirador Capital Partners LP raised its stake in shares of Intuitive Surgical by 1.4% in the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 50 shares during the last quarter. Exome Asset Management LLC lifted its position in shares of Intuitive Surgical by 16.8% during the 3rd quarter. Exome Asset Management LLC now owns 7,427 shares of the medical equipment provider’s stock valued at $3,649,000 after buying an additional 1,069 shares in the last quarter. Consolidated Planning Corp increased its stake in shares of Intuitive Surgical by 17.4% in the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider’s stock worth $3,979,000 after purchasing an additional 1,198 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of Intuitive Surgical by 73.2% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 270,029 shares of the medical equipment provider’s stock valued at $132,657,000 after acquiring an additional 114,149 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock valued at $39,622,000 after acquiring an additional 76,649 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of recent analyst reports. Robert W. Baird increased their price objective on shares of Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Citigroup raised their target price on shares of Intuitive Surgical from $567.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI reiterated a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Piper Sandler restated an “overweight” rating and issued a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Mizuho lifted their price objective on Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $554.17.

Insider Transactions at Intuitive Surgical

In other news, CFO Jamie Samath sold 270 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $540.15, for a total value of $145,840.50. Following the sale, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at approximately $4,730,093.55. This represents a 2.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Gary S. Guthart sold 18,151 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the transaction, the chief executive officer now directly owns 24,219 shares in the company, valued at $12,391,166.97. This represents a 42.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,190 shares of company stock valued at $25,012,927. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Stock Down 2.7 %

Shares of ISRG traded down $14.73 on Monday, hitting $532.74. The company’s stock had a trading volume of 410,623 shares, compared to its average volume of 1,200,329. The firm has a market capitalization of $189.75 billion, a price-to-earnings ratio of 85.65, a P/E/G ratio of 5.31 and a beta of 1.39. The firm’s fifty day moving average price is $535.93 and its 200-day moving average price is $495.17. Intuitive Surgical, Inc. has a fifty-two week low of $355.17 and a fifty-two week high of $556.23.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The firm had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.